ClinicalTrials.gg
WithdrawnNCT06297486KEYSTONE 1Updated Dec 13, 2024

Study of a Gene Therapy Treatment for Hemophilia A

A Phase 3 interventional study of SPK-8011 in Hemophilia A, sponsored by Spark Therapeutics, Inc.. Withdrawn at 27 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by Spark Therapeutics, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment

How we know

Why this study was withdrawn
Strategic Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Hemophilia A by Hoffmann-La Roche — 5 open to participants now, 8 under way, 4 of them phase 3. Hemophilia A · Hoffmann-La Roche.

Enrollment
20th of 20
0 · median 58
Started
2024
the only one that year
Phase 3
12 of 25
3 open now
Registered
21st of 25
by date

Among the 25 studies in Hemophilia A by Hoffmann-La Roche, this one is the 20th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2024, is one of 12 in phase 3, and was the 21st registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

5 of the 25 studies in Hemophilia A by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Hemophilia A by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of SPK-8011 in preventing bleed episodes compared with FVIII prophylaxis in participants with hemophilia A without FVIII inhibitors on routine FVIII prophylaxis.

03

Conditions studied

  • Hemophilia A

Browse trials for

Keywords

  • Dirloctocogene samoparvovec
  • SPK 8011
  • Blood coagulation factor VIII
  • FVIII
  • AAV-Spark200-BDD-hFVIII
  • Gene Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a negative anti-AAV-Spark200 neutralizing antibody (NAb) test result.
  • Are adult males with severe or moderately severe hemophilia A, defined as endogenous FVIII activity ≤3%, as documented by a certified laboratory (historically or during the Screening Period) and where the FVIII:C level is measured more than 96 hours after the prior dose of an extended-half-life FVIII
  • Have ≥150 documented exposure days to an FVIII protein product such as recombinant, plasma-derived, or extended half-life FVIII product
  • Have no prior history of or anaphylaxis associated with the administration of any FVIII product.
  • Have screening hepatic ultrasound without evidence of cirrhosis and no laboratory or clinical evidence per the Investigator's judgment of advanced liver disease or cirrhosis.
  • Have a negative test for inhibitor against FVIII (ie, \<0.6 Bethesda units [BU]) during screening.
  • Have no documented FVIII inhibitor (ie, \<0.6 BU), FVIII half-life \<6 hours, or FVIII recovery \<66% in the 5 years prior to screening.
  • Candidates who completed successful immune tolerance induction (ITI) at least 5 years before screening are eligible, provided they have had no evidence of inhibitor recurrence (permanent or temporary) within 5 years prior to screening as may be indicated by detection of an inhibitor, FVIII half-life \<6 hours, or FVIII recovery \<66% since completing ITI.
  • If (HIV)-positive at screening, have an adequate cluster of differentiation 4 (CD4) count (>200/mm3) and undetectable viral load (\<50 genome copies [gc]/mL), are on an antiretroviral drug regimen, and have completed at least 12 weeks of this treatment regimen prior to screening.
  • Meet the following inclusion criteria by cohort:

    • Cohort A: have documented history of prior treatment with FVIII prophylaxis (defined as receiving a prescribed dose and frequency of FVIII infusions with the intent to treat continuously for 52 weeks per year) for a minimum of 6 months prior to screening; and are willing to continue their FVIII prophylaxis during the Lead-In Period of this study (minimum of 24 weeks).
    • Cohort B: have documented history of prior treatment with FVIII on demand for a minimum of 6 months that shows ≥5 treated bleeds in the last 6 months prior to screening.
    • Cohort C: have documented history of prior treatment with emicizumab prophylaxis for a minimum of 6 months prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Have an inherited or acquired bleeding disorder other than hemophilia A
  • Have inherited or acquired thrombophilia, have signs of thromboembolic disease in the Investigator's judgment, or are on current treatment for thromboembolic disease. A history of previous catheter-associated thrombosis for which anti-thrombotic treatment is not currently ongoing is not considered an exclusion criterion.
  • Have concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study or that would, in the opinion of the Investigator or Sponsor, preclude the candidate's safe participation in and completion of the study, or the interpretation of the study results.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Cohort A (Primary Cohort)

    Participants with severe or moderately severe hemophilia A without FVIII inhibitors using routine FVIII prophylaxis

    Genetic: SPK-8011

  • Experimental
    Cohort B

    Participants with severe or moderately severe hemophilia A without FVIII inhibitors using on-demand FVIII replacement therapy

    Genetic: SPK-8011

  • Experimental
    Cohort C

    Participants with severe or moderately severe hemophilia A without FVIII inhibitors using emicizumab prophylaxis

    Genetic: SPK-8011

Interventions

  • GeneticSPK-8011

    Participants will receive a single dose of SPK-8011, administered by intravenous (IV) infusion, on Day 1.

    Also known as: AAV-Spark200-BDD-hFVIII, Dirloctocogene samoparvovec

06

What researchers measure

Primary outcomes

  1. Annualized Bleed Rate (ABR) for All Bleeds [Cohort A]

    Time frame: Up to 66 weeks post-SPK-8011 infusion

Secondary outcomes

  1. Median FVIII: C levels [Cohort A]

    Time frame: Up to approximately 10 years

  2. ABR for treated bleeds [Cohort A]

    Time frame: Up to approximately 10 years

  3. Percentage of Participants with ABR=0 for all bleeds; treated bleeds; treated spontaneous bleeds; and treated joint and target joint bleeds [Cohort A]

    Time frame: Up to approximately 10 years

  4. ABR for treated spontaneous, joint, and target joint bleeds [Cohort A]

    Time frame: Up to approximately 10 years

  5. Annualized FVIII dosage [Cohort A]

    Time frame: Up to approximately 10 years

  6. Proportion of Resolved Target Joints [Cohort A]

    Time frame: Up to approximately 10 years

  7. Mean Change of Total Hemophilia Joint Health Score [Cohort A]

    Time frame: Baseline, up to 66 weeks post-SPK-8011 infusion

  8. FVIII:C levels over time [Cohort A]

    Time frame: Up to approximately 10 years

  9. Mean ABR for all bleeds and treated bleeds [Cohort C]

    Time frame: Up to approximately 10 years

  10. FVIII: C levels over time from Week 26 [Cohort C]

    Time frame: Up to approximately 10 years

  11. Proportion of Participants Who Receive IV Methylprednisolone (IVMP) Prior to Week 8 (Early IVMP) [Cohorts A, B, C]

    Time frame: Up to approximately 10 years

  12. Proportion of Participants Who Receive Secondary Oral Immunomodulation [Cohorts A, B, C]

    Time frame: Up to approximately 10 years

  13. Median Time to First Immunomodulation-related Corticosteroid Dose [Cohorts A, B, C]

    Time frame: Up to approximately 10 years

  14. Median Duration of Secondary Oral Immunomodulation [Cohorts A, B, C]

    Time frame: Up to approximately 10 years

  15. Proportion of Participants with FVIII Inhibitor Development [Cohorts A, B, C]

    Time frame: Up to approximately 10 years

  16. Proportion of participants with Treatment-related AEs of ALT Elevation [Cohorts A, B, C]

    Time frame: Up to approximately 10 years

  17. Proportion of participants with treatment-related AEs of Infusion Reaction [Cohorts A, B, C]

    Time frame: Up to approximately 10 years

  18. Number of participants with abnormal physical exam findings, abnormal vital signs, and abnormal selected clinical laboratory test results [Cohorts A, B, C]

    Time frame: Up to approximately 10 years

  19. Proportion of participants with AEs and SAEs [Cohorts A, B, C]

    Time frame: Up to approximately 10 years

  20. Proportion of participants with AESIs [Cohorts A, B, C]

    Time frame: Up to approximately 10 years

07

Study locations

27 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Loma Linda University Health
    Loma Linda, California 92354, United States
  • Orthopaedic Institute for Children/Orthopaedic Hemophilia Treatment Center
    Los Angeles, California 90007, United States
  • Kaiser Permanente-Oakland Medical Center
    Oakland, California 94611, United States
  • Kaiser Permanente-Roseville Medical Center
    Roseville, California 95661, United States
  • Kaiser Permanente -Sacramento Medical Center
    Sacramento, California 95814, United States
  • Kaiser Permanente -San Francisco Medical Center
    San Francisco, California 94115, United States
  • University of California - San Francisco
    San Francisco, California 94143, United States
  • Kaiser Permanente- Santa Clara Medical Center
    Santa Clara, California 94115, United States
  • Kaiser Permanente-Vallejo Medical Center
    Vallejo, California 94589, United States
  • Kaiser Permanente -Walnut Creek Medical Center
    Walnut Creek, California 94596, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Newark Beth Israel
    Newark, New Jersey 07112, United States
  • Weill Cornell Medical Hospital
    New York, New York 10065, United States
  • University of North Carolina - Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
  • University Hospitals Cleveland
    Cleveland, Ohio 44106, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Oregon Health & Sciences University
    Portland, Oregon 97239, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19103, United States
  • Cook Children's Hospital
    Fort Worth, Texas 76104, United States
  • The University of Texas Health Science Center at Houston-Gulf States Hemophilia & Thrombosis Center
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84112, United States
  • Bloodworks NW
    Seattle, Washington 98101, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for May 2027, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 29, 2024
First posted
Mar 7, 2024
StartActual
Mar 13, 2024
Primary completionEst.
May 2027
CompletionEst.
Sep 4, 2035
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06297486
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
Mar 13, 2024
Primary completion
May 2027 (estimated)
Completion
Sep 4, 2035 (estimated)
Last update
Dec 13, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion